AIMS/HYPOTHESIS: Increased NEFA production and concentrations may underlie insulin resistance. We examined systemic and adipose tissue NEFA metabolism in insulin-resistant overweight men (BMI 25-35 kg/m2). METHODS: In a cohort study we examined NEFA concentrations in men in the upper quartile of fasting insulin (n = 124) and in men with fasting insulin below the median (n = 159). In a metabolic study we examined NEFA metabolism in the fasting and postprandial states, in ten insulin-resistant men and ten controls. RESULTS: In the cohort study, fasting NEFA concentrations were not significantly different between the two groups (median values: insulin-resistant men, 410 micromol/l; controls, 445 micromol/l). However, triacylglycerol concentrations differed markedly (1.84 vs 1.18 mmol/l respectively, p < 0.001). In the metabolic study, arterial NEFA concentrations again did not differ between groups, whereas triacylglycerol concentrations were significantly higher in insulin-resistant men. Systemic NEFA production and the release of NEFA from subcutaneous adipose tissue, expressed per unit of fat mass, were both reduced in insulin-resistant men compared with controls (fasting values by 32%, p = 0.02, and 44%, p = 0.04 respectively). 3-Hydroxybutyrate concentrations, an index of hepatic fat oxidation and ketogenesis, were lower (p = 0.03). CONCLUSIONS/ INTERPRETATION: Adipose tissue NEFA output is not increased (per unit weight of tissue) in insulin resistance. On the contrary, it appears to be suppressed by high fasting insulin concentrations. Alterations in triacylglycerol metabolism are more marked than those in NEFA metabolism and are indicative of altered metabolic partitioning of fatty acids (decreased oxidation, increased esterification) in the liver.
AIMS/HYPOTHESIS: Increased NEFA production and concentrations may underlie insulin resistance. We examined systemic and adipose tissue NEFA metabolism in insulin-resistant overweight men (BMI 25-35 kg/m2). METHODS: In a cohort study we examined NEFA concentrations in men in the upper quartile of fasting insulin (n = 124) and in men with fasting insulin below the median (n = 159). In a metabolic study we examined NEFA metabolism in the fasting and postprandial states, in ten insulin-resistant men and ten controls. RESULTS: In the cohort study, fasting NEFA concentrations were not significantly different between the two groups (median values: insulin-resistant men, 410 micromol/l; controls, 445 micromol/l). However, triacylglycerol concentrations differed markedly (1.84 vs 1.18 mmol/l respectively, p < 0.001). In the metabolic study, arterial NEFA concentrations again did not differ between groups, whereas triacylglycerol concentrations were significantly higher in insulin-resistant men. Systemic NEFA production and the release of NEFA from subcutaneous adipose tissue, expressed per unit of fat mass, were both reduced in insulin-resistant men compared with controls (fasting values by 32%, p = 0.02, and 44%, p = 0.04 respectively). 3-Hydroxybutyrate concentrations, an index of hepatic fat oxidation and ketogenesis, were lower (p = 0.03). CONCLUSIONS/ INTERPRETATION: Adipose tissue NEFA output is not increased (per unit weight of tissue) in insulin resistance. On the contrary, it appears to be suppressed by high fasting insulin concentrations. Alterations in triacylglycerol metabolism are more marked than those in NEFA metabolism and are indicative of altered metabolic partitioning of fatty acids (decreased oxidation, increased esterification) in the liver.
Authors: Kitt Falk Petersen; Sylvie Dufour; David B Savage; Stefan Bilz; Gina Solomon; Shin Yonemitsu; Gary W Cline; Douglas Befroy; Laura Zemany; Barbara B Kahn; Xenophon Papademetris; Douglas L Rothman; Gerald I Shulman Journal: Proc Natl Acad Sci U S A Date: 2007-07-18 Impact factor: 11.205
Authors: J O Clausen; K Borch-Johnsen; H Ibsen; R N Bergman; P Hougaard; K Winther; O Pedersen Journal: J Clin Invest Date: 1996-09-01 Impact factor: 14.808
Authors: Johan W E Jocken; Dominique Langin; Egbert Smit; Wim H M Saris; Carine Valle; Gabby B Hul; Cecilia Holm; Peter Arner; Ellen E Blaak Journal: J Clin Endocrinol Metab Date: 2007-03-13 Impact factor: 5.958
Authors: Ulf Risérus; Dennis Sprecher; Tony Johnson; Eric Olson; Sandra Hirschberg; Aixue Liu; Zeke Fang; Priti Hegde; Duncan Richards; Leli Sarov-Blat; Jay C Strum; Samar Basu; Jane Cheeseman; Barbara A Fielding; Sandy M Humphreys; Theodore Danoff; Niall R Moore; Peter Murgatroyd; Stephen O'Rahilly; Pauline Sutton; Tim Willson; David Hassall; Keith N Frayn; Fredrik Karpe Journal: Diabetes Date: 2007-11-16 Impact factor: 9.461
Authors: Leanne Hodson; Alex S T Bickerton; Siobhán E McQuaid; Rachel Roberts; Fredrik Karpe; Keith N Frayn; Barbara A Fielding Journal: Diabetes Date: 2007-06-29 Impact factor: 9.461
Authors: David G Cotter; Baris Ercal; Xiaojing Huang; Jamison M Leid; D André d'Avignon; Mark J Graham; Dennis J Dietzen; Elizabeth M Brunt; Gary J Patti; Peter A Crawford Journal: J Clin Invest Date: 2014-10-27 Impact factor: 14.808
Authors: D André d'Avignon; Patrycja Puchalska; Baris Ercal; YingJu Chang; Shannon E Martin; Mark J Graham; Gary J Patti; Xianlin Han; Peter A Crawford Journal: JCI Insight Date: 2018-06-21
Authors: N Turner; G M Kowalski; S J Leslie; S Risis; C Yang; R S Lee-Young; J R Babb; P J Meikle; G I Lancaster; D C Henstridge; P J White; E W Kraegen; A Marette; G J Cooney; M A Febbraio; C R Bruce Journal: Diabetologia Date: 2013-04-26 Impact factor: 10.122
Authors: François Normand-Lauzière; Frédérique Frisch; Sébastien M Labbé; Patrick Bherer; René Gagnon; Stephen C Cunnane; André C Carpentier Journal: PLoS One Date: 2010-06-04 Impact factor: 3.240